[ NATIONAL · MY ]
A national pharmaceutical regulatory agency sitting within the health ministry, registering products and licensing manufacture.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
ASIA-PACIFIC
The Control of Drugs and Cosmetics Regulations 1984, which carry both product registration and establishment licensing. A manufacturer of registered products holds a Manufacturer’s Licence, which also permits it to sell by wholesale or supply those products — the two permissions that are separate in many markets arrive together here.
Through the Manufacturer’s Licence granted under the 1984 Regulations, and through registration of each product. The national pharmaceutical regulatory agency sits inside the health ministry and does both: it registers the product and licenses the premises that make it, so a question raised in one process is visible in the other.
WHAT TRANSFERS
More than usual, and it is written into the agency’s own licensing guidance: where a factory sits in a PIC/S member country, the agency may accept that factory’s current certificate. That is an unusually direct recognition mechanism rather than a general statement of confidence, and it makes the provenance of an existing certificate a live commercial question — which authority issued it, and is it current. It is permissive rather than automatic: the agency may accept it, and the licence is still Malaysian.
The Manufacturer’s Licence permits manufacture of registered products and their sale by wholesale or supply. A company that would need two permissions elsewhere should not assume it needs two here, nor that the single licence stretches beyond the products actually registered.
The agency registers the product and licenses the premises. Inconsistencies between a registration dossier and what a site can demonstrate surface inside a single organisation rather than across two.
Where a foreign factory is in a PIC/S member country, its current certificate may be accepted. Keeping that certificate current and obtaining it from a recognisable authority becomes part of the Malaysian market plan, not just of the home market’s compliance.
The 1984 Regulations cover drugs and cosmetics together. A company with both should expect one regulatory relationship spanning product families that are governed separately in other markets.
A Manufacturer’s Licence under the Control of Drugs and Cosmetics Regulations 1984, which permits manufacture of registered products and their sale by wholesale or supply. Each product must also be registered.
It may. Where the factory is located in a PIC/S member country, the agency may accept its current certificate. That is a permissive route rather than an entitlement, and it does not remove the need for the Malaysian licence.
They sit in the same instrument. The Control of Drugs and Cosmetics Regulations 1984 cover both, so a company handling both product families deals with one regulatory framework rather than two.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Malaysia: requirements still arrive through the authorities below, and the edition in force is theirs to state.
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.